Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 9/20 | 0.43 |
| ▸ | THRA | P10827 | 6/20 | 0.43 |
| ▸ | VDR | P11473 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7658947 | 1.00 | VCAM1 (0.47) | VCAM1ENPP2RAD51THRBTHRA | |
| SCHEMBL7659049 | 0.94 | VCAM1 (0.53) | VCAM1ENPP2RAD51THRBTHRA | |
| SCHEMBL7662894 | 0.94 | VCAM1 (0.53) | VCAM1ENPP2RAD51THRBTHRA | |
| SCHEMBL8019665 | 0.90 | VCAM1 (0.48) | VCAM1ENPP2RAD51THRBTHRA | |
| SCHEMBL8019666 | 0.90 | VCAM1 (0.48) | VCAM1ENPP2RAD51THRBTHRA | |
| SCHEMBL7664975 | 0.84 | RAD51 (0.53) | ENPP2RAD51MEN1KMT2A | |
| SCHEMBL7664967 | 0.84 | RAD51 (0.53) | ENPP2RAD51MEN1KMT2A | |
| SCHEMBL7667762 | 0.82 | ENPP2 (0.54) | ENPP2RAD51MEN1MAPTKMT2A | |
| SCHEMBL7667811 | 0.82 | ENPP2 (0.54) | ENPP2RAD51MEN1MAPTKMT2A | |
| SCHEMBL7659054 | 0.80 | ALDH1A1 (0.49) | VCAM1RAD51MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020111369-A1 | Aryl sulfonic acids and derivatives as FSH antagonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-08-15 | — | — | US | disclosed |
| US-6355633-B1 | CONTRACEPTIVES | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-12 | — | — | US | disclosed |
| WO-2000058277-A1 | ARYL SULFONIC ACIDS AND DERIVATIVES AS FSH ANTAGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111369-A1 | Aryl sulfonic acids and derivatives as FSH antagonists | FSHR, GNRHR, LHCGR | VCAM1 3121/4885ENPP2 1903/4885RAD51 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.